Full text is available at the source.
A network meta‐analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
Comparing blood sugar control in type 2 diabetes patients treated with once-weekly exenatide, daily liraglutide, insulin glargine, twice-daily exenatide, or placebo
AI simplified
Abstract
Estimated mean differences in HbA1c were -1.15% for Exenatide once weekly, -1.01% for liraglutide 1.2 mg, and -1.18% for liraglutide 1.8 mg.
- Exenatide once weekly showed a significant reduction in HbA1c compared to placebo.
- Liraglutide 1.2 mg also indicated a meaningful reduction in HbA1c relative to placebo.
- The difference in HbA1c reduction between Exenatide once weekly and liraglutide 1.2 mg was -0.14%, which was not statistically significant.
- A negligible difference of 0.03% was observed between Exenatide once weekly and liraglutide 1.8 mg.
- The comparison of liraglutide 1.2 mg and 1.8 mg resulted in a mean HbA1c difference of 0.17%, suggesting minimal variability in their effectiveness.
AI simplified